No interaction of memantine with acetylcholinesterase inhibitors approved for clinical use.
about
N-methyl D-aspartate (NMDA) receptor antagonists and memantine treatment for Alzheimer's disease, vascular dementia and Parkinson's diseaseMemantine and cholinesterase inhibitors: complementary mechanisms in the treatment of Alzheimer's diseasePharmacodynamics of memantine: an update.Potential role of the combination of galantamine and memantine to improve cognition in schizophreniaEvaluation of memantine for neuroprotection in dementia.The lipophilic bullet hits the targets: medicinal chemistry of adamantane derivativesAcetylcholineestarase-inhibiting alkaloids from Lycoris radiata delay paralysis of amyloid beta-expressing transgenic C. elegans CL4176Evaluation of memantine for the treatment of Alzheimer's disease.The benefits and risks associated with cholinesterase inhibitor therapy in Alzheimer's disease.Donepezil markedly potentiates memantine neurotoxicity in the adult rat brainMemantine in the treatment of mild-to-moderate Alzheimer's disease.Memantine combined with an acetyl cholinesterase inhibitor - hope for the future?Memantine in dementia: a review of the current evidence.Rationale for combining glutamatergic and cholinergic approaches in the symptomatic treatment of Alzheimer's disease.Benefits and risks of add-on therapies for Alzheimer's disease.Lack of pharmacokinetic or pharmacodynamic interaction between memantine and donepezil.Pharmacoeconomic aspects of memantine (Ebixa) in the treatment of Alzheimer's disease.A Chinese Herbal Formula, Gengnianchun, Ameliorates β-Amyloid Peptide Toxicity in a Caenorhabditis elegans Model of Alzheimer's Disease.Steady-state pharmacokinetics of galantamine are not affected by addition of memantine in healthy subjects.Shengmai Formula Ameliorates Pathological Characteristics in AD C. elegans.
P2860
Q26825619-42AAB3A6-2987-4938-82F3-1144B8409CD3Q27025207-9CB7F808-B9C1-42DA-B6DF-DDA01341963DQ30490604-132A9E55-1632-4D32-BC15-3BD43DE6F6E1Q33905343-0F781808-6D46-4425-948C-44FECFC4BA5DQ34074926-24D6C98E-B322-49B2-B567-E1D90F219A11Q34329204-0E348A41-9CF9-4A53-BBC3-E6BE2ABD3FDFQ34723124-7513DD2E-02CE-4D8D-9240-5AC350A1B3DDQ35594009-782F9850-6F55-4A6C-87C0-11F9B3056E6EQ35873720-51C5A403-01A4-4936-AFBB-2842D05428B0Q36465064-6D3032DB-246E-4168-9427-94A4402D03A1Q36719691-F1DDE7BD-37D3-4594-A07E-9EA8B2B6C49DQ37165577-758A8561-F169-45BB-9E40-D76985EF2870Q37850821-19FF739F-99A8-40D3-BDC5-E1DBC3CF95BCQ38066972-93D9B242-868B-4D9A-87D3-8A18AC4EA5D0Q38620338-E872F57A-FADC-4E86-A038-39FD5EF82F45Q42631839-D5340AD0-8BD6-495E-A167-A29F4BF77ABFQ43266420-9AF8423F-3943-42DB-BD6D-8277F2CE0148Q46242516-B3D70875-96B5-491C-8EE6-87BED28989EBQ46438866-13B1685F-6EC9-4CE9-B151-A4D0C27E964FQ53373650-DF3B8EA0-3CBE-4C8E-8210-E6CE4907484C
P2860
No interaction of memantine with acetylcholinesterase inhibitors approved for clinical use.
description
2000 nî lūn-bûn
@nan
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
2000年论文
@zh
2000年论文
@zh-cn
name
No interaction of memantine wi ...... ors approved for clinical use.
@en
No interaction of memantine wi ...... ors approved for clinical use.
@nl
type
label
No interaction of memantine wi ...... ors approved for clinical use.
@en
No interaction of memantine wi ...... ors approved for clinical use.
@nl
prefLabel
No interaction of memantine wi ...... ors approved for clinical use.
@en
No interaction of memantine wi ...... ors approved for clinical use.
@nl
P2093
P1433
P1476
No interaction of memantine wi ...... ors approved for clinical use.
@en
P2093
P304
P356
10.1016/S0024-3205(00)00411-2
P407
P577
2000-02-01T00:00:00Z